| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4b1549a3bcf5e6be774f2791a1f1ad5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-3337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-0266
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0061 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M39-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-703 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-30 |
| filingDate |
2005-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b47697f94e48da8036e0efef9675728d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87278ce1ee6f7e868fd753c70a3261dd |
| publicationDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2005284908-B2 |
| titleOfInvention |
Biosynchronous transdermal drug delivery |
| abstract |
A delivery mechanism and device for the passive periodic release of a drug or an active ingredient and the methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms. This strategy is intended to counteract disease states and symptoms when they are likely to be at their worst by using an automated and pre-programmable transdermal or other drug administration system. |
| priorityDate |
2004-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |